IMVARIA develops AI-driven digital biomarkers that analyze imaging and lab data to provide non-invasive diagnostic support for interstitial lung disease, particularly idiopathic pulmonary fibrosis. Their FDA-authorized tool, Fibresolve, enables clinicians to classify disease subtypes and expedite diagnosis, reducing the need for invasive biopsy procedures.
Funding
$3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing interstitial lung diseases (ILD), particularly idiopathic pulmonary fibrosis (IPF), often requires invasive biopsy procedures due to the difficulty in differentiating disease subtypes through traditional methods. Delayed or inaccurate diagnoses can lead to improper treatment and poorer patient outcomes.
Solution
IMVARIA provides AI-driven digital biomarkers that analyze imaging and lab data to provide non-invasive diagnostic support for ILD. Their FDA-authorized tool, Fibresolve, assists clinicians in classifying disease subtypes and expediting diagnosis, potentially reducing the need for invasive biopsies. The AI Lab operates as a centralized, cloud-based digital lab, analyzing transmitted cases and returning reports with results in minutes. The platform supports various imaging modalities and data types, adhering to international quality compliance standards.
Target Audience
The primary target audience includes pulmonologists, radiologists, and other clinicians involved in the diagnosis and management of interstitial lung diseases, as well as clinical trialists.
Features
- AI-driven analysis of lung computed tomography (CT) imaging data
- Diagnostic subtype classification in suspected cases of interstitial lung disease (ILD)
- Fibresolve: FDA-authorized AI diagnostic tool for idiopathic pulmonary fibrosis (IPF)
- Non-invasive assessment, reducing the need for traditional biopsy
- Cloud-based digital lab for data analysis and report generation
- Machine learning algorithms for disease assessment and prediction
- Support for various imaging modalities (CT, MRI) and data types (lab results)